melanotan 1 dosage: Frequently asked questions

Increasing the loading dose above 0.16mg/kg does not accelerate pigmentation. It increases nausea risk without additional melanogenic benefit. The rate-limiting step is tyrosinase upregulation and melanosome maturation, not MC1R occupancy. Once receptors are saturated (achieved at 0.16mg/kg), adding more peptide just increases circulating levels that will be renally cleared before receptors recycle. Clinical trials using 0.20mg/kg showed identical pigmentation timelines to 0.16mg/kg but 3× higher nausea rates. If you need visible pigmentation in fewer than 10 days, combine Melanotan-1 with controlled UV exposure (10–15 minutes daily at peak UVI). The dual stimulus (peptide + photons) accelerates eumelanin migration to the stratum corneum by 2–3 days compared to peptide alone.

You cannot pharmacologically compress melanogenesis below 14 days—tyrosinase upregulation and eumelanin polymerisation are enzymatic processes with fixed kinetics. Doubling the dose does not halve the time. Trials using 2mg daily doses showed the same pigmentation timeline as 0.75mg daily protocols but with 3× the incidence of nausea and spontaneous erections (males). The rate-limiting step is melanocyte synthetic capacity, not MC1R occupancy. Adding minimal UV exposure (1–2 MEDs weekly via controlled sun exposure or UVB phototherapy) can accelerate visible darkening by 20–30%, but this reintroduces DNA damage pathways the peptide was designed to avoid.

Continue the protocol through day 21 before adjusting dose. Melanogenesis lag time in fair-skinned individuals (Fitzpatrick skin types I–II) averages 12–16 days from first injection to visible pigmentation. If no pigmentation appears by day 21 at 1.0mg daily, verify peptide purity and reconstitution accuracy. Underdosing due to incorrect bacteriostatic water volume is the most common cause. A 5mg vial reconstituted with 2.5mL bacteriostatic water yields 2mg/mL concentration; injecting 0.5mL delivers 1mg, not 0.5mg. Recalculate your dosing volume before increasing dose above 1.0mg daily.

Nausea from Melanotan-1 peaks 30–90 minutes post-injection and is mediated by melanocortin-4 receptor (MC4R) activation in the hypothalamus, not photoprotection pathways. If nausea persists beyond 4 hours or worsens over consecutive doses, reduce dose by 30% and inject before bed to sleep through peak side effects. Ginger supplementation (1000mg) or ondansetron (if prescribed) taken 30 minutes before injection reduces nausea incidence by approximately 40% in clinical observation. Persistent nausea beyond two weeks at reduced dose suggests MC4R hypersensitivity. Consult a physician before continuing.

Recalculate concentration using actual mass from certificate of analysis or analytical balance measurement. If a vial labeled 10mg tests at 9.4mg and you reconstituted with 2mL water, actual concentration is 4.7mg/mL, not 5mg/mL. To deliver a true 1mg dose at 4.7mg/mL, inject 0.213mL (21.3 units), not the 0.2mL you'd use at 5mg/mL. Failing to adjust means every dose is 6% lower than intended—this compounds across weeks of administration and can explain why response plateaus unexpectedly. High-precision research teams weigh vials on analytical balances (±0.001g) before reconstitution and after removing the peptide cake to determine exact content.

Body-weight dosing requires accuracy within ±2kg to maintain dose precision within ±5%. If you estimate 75kg but actual weight is 78kg, a 0.2mg/kg protocol calculates as 15mg vs 15.6mg total—acceptable variance for exploratory research but unacceptable for dose-response studies. Use a calibrated scale before beginning any weight-adjusted protocol. For multi-week studies, reweigh at each dose escalation point; body composition changes during melanocortin research can shift optimal mg/kg ratios even if total weight remains stable.

Convert milligrams to micrograms by multiplying by 1000: 1mg = 1000mcg. If your protocol specifies 500mcg (0.5mg) dose at 5mg/mL concentration, calculate injection volume as 0.5mg ÷ 5mg/mL = 0.1mL (10 units). Some research protocols cite melanocortin doses in micrograms because effective ranges span 250–2000mcg—expressing in mcg avoids decimal confusion. Always verify whether published doses use mg or mcg units; a 1000-fold error from unit confusion would deliver massively supratherapeutic or subtherapeutic doses.

You've diluted the peptide below target concentration—this cannot be reversed by removing water, as peptide is now dissolved throughout the volume. If you added 3mL instead of 2mL to a 10mg vial, concentration is 3.33mg/mL instead of 5mg/mL. To deliver 1mg dose, inject 0.3mL (30 units) instead of 0.2mL. The limitation: larger injection volumes (above 0.5mL subcutaneous) can cause injection-site discomfort and slower absorption. If dilution error produces concentrations requiring volumes above 0.5mL per dose, consider the vial unusable for that protocol and reconstitute a fresh vial with correct volume.

Missing doses in research protocols should be handled according to pre-specified study procedures, typically involving administration as soon as possible if <4 hours from scheduled time.[1] If >4 hours have elapsed, most protocols recommend skipping the missed dose and resuming the regular schedule to avoid dose stacking and potential adverse effects.[2] All missed doses must be documented as protocol deviations and reported according to institutional guidelines.[3]

Verify reconstitution accuracy and injection technique before assuming non-response. Calculate actual delivered dose: for a 10mg vial reconstituted with 2.0mL bacteriostatic water, 1.0mg requires exactly 0.2mL injection volume. Researchers using insulin syringes (marked in units, not mL) frequently miscalculate conversions. Second, confirm subcutaneous rather than intradermal injection. Intradermal administration produces localized pigmentation at injection sites rather than systemic melanogenesis. Third, assess baseline skin phototype: individuals with Fitzpatrick Type I skin (very fair, always burns) demonstrate slower melanogenic response than Type III–IV even with identical receptor activation. If technique is verified and 21 days elapse with no response, consider increasing to 1.5mg daily or checking peptide storage temperature logs for excursions.

Reduce to 1.0mg and extend titration interval. Nausea from melanocortin agonism reflects MC4R activation in the area postrema (brainstem chemoreceptor trigger zone). It is dose-dependent, predictable, and manageable through slower escalation. Administering doses with food slightly delays absorption and blunts peak plasma concentration, reducing nausea intensity without eliminating peptide efficacy. Antiemetic premedication (ondansetron 4mg, 30 minutes before injection) blocks serotonin-mediated nausea but does not interfere with melanocortin receptor signaling. Acceptable for human research protocols where nausea compromises subject retention.

Discard it immediately. Melanocortin peptides undergo measurable degradation within 8–12 hours at temperatures above 15°C. A full overnight period at 20–22°C renders concentration calculations unreliable even if the solution appears clear. The degradation involves hydrolysis of peptide bonds and oxidation of methionine residues, producing fragment peptides that retain partial receptor affinity but unpredictable pharmacokinetics. Using compromised peptide introduces systematic measurement error that statistical analysis cannot correct. The cost of discarding one vial is trivial compared to invalidating an entire study cohort's data.

Maintain consistent timing moving forward but do not attempt retrospective correction. Melanocortin receptor occupancy fluctuates with plasma peptide concentration. Injections administered at 8:00 AM produce different 24-hour receptor activation patterns than injections at 2:00 PM due to circadian variation in endogenous α-MSH secretion and receptor sensitivity. Protocols measuring acute effects (cardiovascular response within 60 minutes post-dose) require strict timing adherence; studies measuring cumulative outcomes (total melanin content after eight weeks) tolerate moderate timing variation. Document all deviations in study logs. Reviewers scrutinizing methodology will assess whether timing inconsistency meaningfully impacts conclusions.

Verify peptide integrity first. Degraded or improperly reconstituted Melanotan-1 loses melanogenic activity without visible changes to solution clarity. If stored correctly, the issue is likely inadequate UV exposure. Melanotan-1 stimulates melanocyte tyrosinase activity, but melanin polymerisation into visible pigment requires either natural sunlight or controlled UVA at 10–15 minutes per session, two to three times weekly. Without UV stimulus, melanin precursors accumulate without darkening. Add brief UVA exposure starting on day seven of your protocol.

Maintaining elevated eumelanin levels indefinitely requires either continuous low-frequency dosing (0.5mg once weekly minimum) or regular UV exposure to sustain melanocyte activity. Melanin turnover in keratinocytes follows a 14–21 day cycle as skin cells migrate from the basal layer to the stratum corneum and shed. Without ongoing melanogenic stimulus, pigmentation fades to baseline within 4–6 weeks. The lowest effective maintenance frequency we've observed in research protocols is 0.5mg every 10 days combined with twice-weekly brief UVA sessions, but individual variation is significant.

Reduce your daily dose by 0.25mg and hold at that level for five days before attempting further escalation. Melanocortin receptor activation in the area postrema (the brainstem region controlling nausea) varies significantly between individuals. Approximately 15% of users cannot tolerate doses above 0.5mg regardless of titration speed. If nausea persists below 0.5mg daily, Melanotan-1 may not be suitable for you. Alternative approaches include splitting doses into twice-daily 0.25mg injections to blunt peak plasma concentration, or switching to Melanotan-2, which has lower nausea incidence at equivalent melanogenic doses due to different receptor binding kinetics.